Ventyx Biosciences (VTYX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

VTYX Ventyx Biosciences

Watchlist

1.745
+0.035+2.05%

Trading Feb 18 11:23 ET

123.39MMarket Cap-0.74P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Ventyx Biosciences Announces Presentation of Data From the Phase 2 Trial of Allosteric Tyk2 Inhibitor Vtx958 in Crohn’s Disease at Ecco 2025
ReutersFeb 18 08:00 ET
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswireFeb 5 08:00 ET
H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating
Moomoo NewsJan 14 12:31 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciencesto Neutral
BenzingaJan 14 12:29 ET
Ventyx Announces Phase 2 Trials For VTX2735, VTX3232; Obesity Data Expected H2 2025, Parkinson's Data H1 2025; $252.9M Funding Extends To H2 2026
BenzingaJan 14 08:15 ET
Ventyx Biosciences Highlights Its 2025 Pipeline Strategy
TipRanksJan 14 08:11 ET

Comments

Jaguar8

3 hours ago

NEWS

$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
Tuesday, 18th February at 8:00 am
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers
Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958
...

Trytosaveabit

3 hours ago

update

$Ventyx Biosciences (VTYX.US)$ Reuters· just
Ventyx Biosciences Announces Presentation of Data From the Phase 2 Trial of Allosteric Tyk2 Inhibitor Vtx958 in Crohn’s Disease at Ecco 2025

Jaguar8

Feb 10 18:48

🟤Watchlist, FEBRUARY 11,2025, Tuesday. NFA - DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...

Jaguar8

Feb 10 12:07

13G filed 5.72%

$Ventyx Biosciences (VTYX.US)$

Tonyco

Nov 29, 2024 19:20

Columns Pay me

Here have some gifts, my weekend work so far:
$Yalla (YALA.US)$ diversity outside Asia/us, expanding reach
$NexGel (NXGL.US)$ specialized medical applications will see higher demand as the saline shortage goes on, and more look to alternatives
$Lumen Technologies (LUMN.US)$ ongoing transitions, personally see an increase in presence (which is impressive, honestly, I'm a nobody in random town), and they are approaching good buy levels
$Rezolute (RZLT.US)$ also approaching oversold
$Ventyx Biosciences (VTYX.US)$ impressiv...

VTYX Ventyx Biosciences

Trade Overview

Capital Trend

News

Comments

Trending Stocks